Tifcemalimab

Advanced NSCLC

Shanghai Junshi Bioscience Co., Ltd.monoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

1205 Active assets in the Advanced NSCLC cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

Tifcemalimab is also rated in:

small cell lung carcinomaDormant

BB

Indicative ·

66 / 100

Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous ImmunotherapyDormant

CCC

Indicative ·

53 / 100

Hodgkins lymphomaDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.